FDA: Doctors should use genetic test before prescribing abacavir
The FDA is expected to release an advisory today that calls on doctors to use a genetic test before prescribing abacavir -- sold by GlaxoSmithKline under the name Ziagen -- to prevent severe allergic reactions in patients carrying an immune-system gene variant. The recommendation will be included in a "black box" warning on Ziagen's new label, which will also mention the increased risk of heart attack based on "inconclusive" study data.
New York Times, The | 07/24
This story published in BIO SmartBrief on 07/24/2008
More from SmartBrief:
Novartis test identifies liver risk in Prexige patients
Monday, August 3, 2009
Immucor submits 30-day working response to FDA
Tuesday, August 11, 2009
Trade group recommends FDA safety seal for online drug, device data
Tuesday, November 10, 2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|